Author

Soumya Chataverdi

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5116081463

Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia

2025 · Philip D. Harvey, Inder Kaul, et al. · Schizophrenia Research · 10

Effects of Xanomeline and Trospium Chloride for Negative Symptoms Associated With Physical Activity in Younger and Older Adults with Schizophrenia: Results From a 52-Week, Open-label Clinical Trial

2026 · Philip D. Harvey, Inder Kaul, et al. · Schizophrenia Research · 1

Works count: 2

Citation count: 11

H-index: 1

I10-index: 1